HighPoint Advisor Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

HighPoint Advisor Group’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$45K	Buy	+1,136	New	+$51.2K	﹤0.01%	516
2021 Q3	$56K	Hold	1,136	–	–	0.01%	542
2021 Q2	$65K	Buy	1,136 +67	+6%	+$3.58K	0.01%	529
2021 Q1	$59K	Buy	1,069 +20	+2%	+$1.51K	0.01%	487
2020 Q4	$115K	Buy	1,049 +147	+16%	+$20K	0.01%	456
2020 Q3	$149K	Hold	902	–	–	0.03%	357
2020 Q2	$151K	Hold	902	–	–	0.03%	325
2020 Q1	$82K	Buy	+902	New	+$70.4K	0.02%	326

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighPoint Advisor Group's BCLI Position: Q2 2022 in Review

HighPoint Advisor Group opened a new position in BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2022: 1,136 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #516 among its holdings. This is a return to the name: HighPoint Advisor Group previously reported a position in BCLI as recently as Q3 2021.

HighPoint Advisor Group first reported a position in BCLI in Q1 2020 and has held it in 8 quarters since. The position peaked at $151K in Q2 2020. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2022.

HighPoint Advisor Group held 1,136 shares of BRAINSTORM CELL THERAPUTC worth $45K as of Q2 2022.
BRAINSTORM CELL THERAPUTC was a new HighPoint Advisor Group position in Q2 2022.
BRAINSTORM CELL THERAPUTC made up ﹤0.01% of HighPoint Advisor Group's portfolio in Q2 2022, its #516 holding.
HighPoint Advisor Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and has held it in 8 quarters since.
HighPoint Advisor Group's BRAINSTORM CELL THERAPUTC position peaked at $151K in Q2 2020.
48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2022.

Based on HighPoint Advisor Group's 13F filing for Q2 2022, filed 15 Aug 2022.